Anticancer effects of resveratrol in canine hemangiosarcoma cell lines

A. Carlson, K. S. Alderete, M. K.O. Grant, Davis Seelig, L. C. Sharkey, Beshay Zordoky

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Hemangiosarcoma (HSA) is a highly malignant tumour with aggressive biological behaviour. HSAs are more common in dogs than other domestic animals. The median survival time of dogs with HSA remains short, even with chemotherapy and surgery. Therefore, there is a critical need to improve the adjuvant chemotherapeutic regimens to improve clinical outcomes in dogs with HSA. Resveratrol has been shown to possess strong anti-proliferative and/or pro-apoptotic properties in human cancer cell lines. Nevertheless, the potential anticancer effects of resveratrol have not been reported in canine HSAs. The objective of this study is to determine the growth inhibitory effects of resveratrol in HSA cells when used alone or in combination with doxorubicin, a commonly used chemotherapeutic agent. Frog and DD-1 canine HSA cell lines were treated with varying concentrations of resveratrol with and without doxorubicin. Cell viability was measured by the MTT assay. The expression of apoptotic proteins, activation of p38 mitogen-activated protein kinase (MAPK), AMP-activated protein kinase (AMPK) and extracellular signal-regulated kinase 1/2 (ERK1/2) were assessed by western blotting. Similar to human cancer cell lines, resveratrol markedly inhibited the growth and induced apoptosis in both HSA cell lines. Mechanistically, resveratrol activated p38 MAPK, but did not affect the AMPK or the ERK1/2 pathways. Additional experiments showed that resveratrol augmented the growth-inhibitory and apoptotic effects of doxorubicin in both HSA cell lines. These findings suggest that resveratrol has pro-apoptotic effects in canine HSA cells; therefore, its use as a potential adjunct therapy in canine HSA patients warrants further investigation.

Original languageEnglish (US)
Pages (from-to)253-261
Number of pages9
JournalVeterinary and Comparative Oncology
Volume16
Issue number2
DOIs
StatePublished - Jun 1 2018

Fingerprint

hemangiosarcoma
Hemangiosarcoma
resveratrol
Canidae
cell lines
Cell Line
dogs
mitogen-activated protein kinase
doxorubicin
Doxorubicin
AMP-activated protein kinase
Mitogen-Activated Protein Kinase 3
Mitogen-Activated Protein Kinase 1
p38 Mitogen-Activated Protein Kinases
Dogs
Growth
antineoplastic activity
Neoplasms
AMP-Activated Protein Kinases
Domestic Animals

Keywords

  • apoptosis
  • canine
  • doxorubicin
  • hemangiosarcoma
  • resveratrol

PubMed: MeSH publication types

  • Journal Article

Cite this

Anticancer effects of resveratrol in canine hemangiosarcoma cell lines. / Carlson, A.; Alderete, K. S.; Grant, M. K.O.; Seelig, Davis; Sharkey, L. C.; Zordoky, Beshay.

In: Veterinary and Comparative Oncology, Vol. 16, No. 2, 01.06.2018, p. 253-261.

Research output: Contribution to journalArticle

Carlson, A. ; Alderete, K. S. ; Grant, M. K.O. ; Seelig, Davis ; Sharkey, L. C. ; Zordoky, Beshay. / Anticancer effects of resveratrol in canine hemangiosarcoma cell lines. In: Veterinary and Comparative Oncology. 2018 ; Vol. 16, No. 2. pp. 253-261.
@article{45aeee96802f4bcd9f1df57bdf9e1e4a,
title = "Anticancer effects of resveratrol in canine hemangiosarcoma cell lines",
abstract = "Hemangiosarcoma (HSA) is a highly malignant tumour with aggressive biological behaviour. HSAs are more common in dogs than other domestic animals. The median survival time of dogs with HSA remains short, even with chemotherapy and surgery. Therefore, there is a critical need to improve the adjuvant chemotherapeutic regimens to improve clinical outcomes in dogs with HSA. Resveratrol has been shown to possess strong anti-proliferative and/or pro-apoptotic properties in human cancer cell lines. Nevertheless, the potential anticancer effects of resveratrol have not been reported in canine HSAs. The objective of this study is to determine the growth inhibitory effects of resveratrol in HSA cells when used alone or in combination with doxorubicin, a commonly used chemotherapeutic agent. Frog and DD-1 canine HSA cell lines were treated with varying concentrations of resveratrol with and without doxorubicin. Cell viability was measured by the MTT assay. The expression of apoptotic proteins, activation of p38 mitogen-activated protein kinase (MAPK), AMP-activated protein kinase (AMPK) and extracellular signal-regulated kinase 1/2 (ERK1/2) were assessed by western blotting. Similar to human cancer cell lines, resveratrol markedly inhibited the growth and induced apoptosis in both HSA cell lines. Mechanistically, resveratrol activated p38 MAPK, but did not affect the AMPK or the ERK1/2 pathways. Additional experiments showed that resveratrol augmented the growth-inhibitory and apoptotic effects of doxorubicin in both HSA cell lines. These findings suggest that resveratrol has pro-apoptotic effects in canine HSA cells; therefore, its use as a potential adjunct therapy in canine HSA patients warrants further investigation.",
keywords = "apoptosis, canine, doxorubicin, hemangiosarcoma, resveratrol",
author = "A. Carlson and Alderete, {K. S.} and Grant, {M. K.O.} and Davis Seelig and Sharkey, {L. C.} and Beshay Zordoky",
year = "2018",
month = "6",
day = "1",
doi = "10.1111/vco.12375",
language = "English (US)",
volume = "16",
pages = "253--261",
journal = "Veterinary and Comparative Oncology",
issn = "1476-5829",
publisher = "Wiley-Blackwell",
number = "2",

}

TY - JOUR

T1 - Anticancer effects of resveratrol in canine hemangiosarcoma cell lines

AU - Carlson, A.

AU - Alderete, K. S.

AU - Grant, M. K.O.

AU - Seelig, Davis

AU - Sharkey, L. C.

AU - Zordoky, Beshay

PY - 2018/6/1

Y1 - 2018/6/1

N2 - Hemangiosarcoma (HSA) is a highly malignant tumour with aggressive biological behaviour. HSAs are more common in dogs than other domestic animals. The median survival time of dogs with HSA remains short, even with chemotherapy and surgery. Therefore, there is a critical need to improve the adjuvant chemotherapeutic regimens to improve clinical outcomes in dogs with HSA. Resveratrol has been shown to possess strong anti-proliferative and/or pro-apoptotic properties in human cancer cell lines. Nevertheless, the potential anticancer effects of resveratrol have not been reported in canine HSAs. The objective of this study is to determine the growth inhibitory effects of resveratrol in HSA cells when used alone or in combination with doxorubicin, a commonly used chemotherapeutic agent. Frog and DD-1 canine HSA cell lines were treated with varying concentrations of resveratrol with and without doxorubicin. Cell viability was measured by the MTT assay. The expression of apoptotic proteins, activation of p38 mitogen-activated protein kinase (MAPK), AMP-activated protein kinase (AMPK) and extracellular signal-regulated kinase 1/2 (ERK1/2) were assessed by western blotting. Similar to human cancer cell lines, resveratrol markedly inhibited the growth and induced apoptosis in both HSA cell lines. Mechanistically, resveratrol activated p38 MAPK, but did not affect the AMPK or the ERK1/2 pathways. Additional experiments showed that resveratrol augmented the growth-inhibitory and apoptotic effects of doxorubicin in both HSA cell lines. These findings suggest that resveratrol has pro-apoptotic effects in canine HSA cells; therefore, its use as a potential adjunct therapy in canine HSA patients warrants further investigation.

AB - Hemangiosarcoma (HSA) is a highly malignant tumour with aggressive biological behaviour. HSAs are more common in dogs than other domestic animals. The median survival time of dogs with HSA remains short, even with chemotherapy and surgery. Therefore, there is a critical need to improve the adjuvant chemotherapeutic regimens to improve clinical outcomes in dogs with HSA. Resveratrol has been shown to possess strong anti-proliferative and/or pro-apoptotic properties in human cancer cell lines. Nevertheless, the potential anticancer effects of resveratrol have not been reported in canine HSAs. The objective of this study is to determine the growth inhibitory effects of resveratrol in HSA cells when used alone or in combination with doxorubicin, a commonly used chemotherapeutic agent. Frog and DD-1 canine HSA cell lines were treated with varying concentrations of resveratrol with and without doxorubicin. Cell viability was measured by the MTT assay. The expression of apoptotic proteins, activation of p38 mitogen-activated protein kinase (MAPK), AMP-activated protein kinase (AMPK) and extracellular signal-regulated kinase 1/2 (ERK1/2) were assessed by western blotting. Similar to human cancer cell lines, resveratrol markedly inhibited the growth and induced apoptosis in both HSA cell lines. Mechanistically, resveratrol activated p38 MAPK, but did not affect the AMPK or the ERK1/2 pathways. Additional experiments showed that resveratrol augmented the growth-inhibitory and apoptotic effects of doxorubicin in both HSA cell lines. These findings suggest that resveratrol has pro-apoptotic effects in canine HSA cells; therefore, its use as a potential adjunct therapy in canine HSA patients warrants further investigation.

KW - apoptosis

KW - canine

KW - doxorubicin

KW - hemangiosarcoma

KW - resveratrol

UR - http://www.scopus.com/inward/record.url?scp=85046539747&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85046539747&partnerID=8YFLogxK

U2 - 10.1111/vco.12375

DO - 10.1111/vco.12375

M3 - Article

VL - 16

SP - 253

EP - 261

JO - Veterinary and Comparative Oncology

JF - Veterinary and Comparative Oncology

SN - 1476-5829

IS - 2

ER -